The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent to 30 different telehealth companies that market compounded versions of ...

The FDA has issued 30 warning letters to telehealth companies over misleading claims about compounded GLP-1 drugs. Regulators say some companies im ...

The FDA has issued 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites. The letters cite violations including claims ...

The Food and Drug Administration (FDA) on Tuesday sent 30 telehealth companies warning letters about their “illegal” sales of ...

March 4, 2026 - The U.S. Food and Drug Administration on Tuesday announced the issuance of 30 warning letters to telehealth companies for making false or misleading claims regarding compounded GLP-1 ...

The U.S. Food and Drug Administration (FDA) has issued warning letters to 30 telehealth companies citing false or misleading claims about compounded GLP-1 weight-loss products on their websites. The ...

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...

Consumer health advertising is driving many employees to take action on GLP-1s. But without guidance, those decisions could be risky.

Hims & Hers reversed course on its launch of a cheaper, copycat version of Novo Nordisk’s GLP-1 weight loss pill amid legal action. In a Feb. 7 social media post, the San Francisco-based telehealth ...

A federal appeals court has handed a win to Cigna, affirming the dismissal of a class action lawsuit that alleged the insurer’s exclusion of weight loss drug coverage amounted to disability ...

The World Health Organization has issued its first guidance on the use of GLP-1 therapies for chronic, relapsing obesity, making it part of the agency’s broader plan to address the global obesity ...